Biovica International Ab Class B · OMXSTO:BIOVIC_B

Biovica International Ab Class B — Q2 2025 Earnings Presentation

37 slides from Biovica International Ab Class B's earnings presentation, Dec 12, 2024

Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q2 Interim Report
Q2 Interim Report Anders Rylander CEO Anders Morén CFO Hector Tamburini Head of US Operations Henrik Winther SVP Business Development 3 ©2024 Biovica International AB
Slide 4: Agenda
Agenda Biovica Introduction Q2 Highlights Financial Update US Update Pharma Services Summary and Q&A ©2023 Biovica International AB – Proprietary and Confidential. ©2024 ©2023 All rights reserved. Biovica International AB
Slide 5: Q&A Session
Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities AG • Luísa Morgado – van Lanschot Kempen 5 ©2024 Biovica International AB
Slide 7: DiviTum TKa
DiviTum® TKa An early indicator of cancer treatment effectiveness + References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy. ©2024 Biovica International AB
Slide 8: Strong scientific evidence that is still growing!
Strong scientific evidence that is still growing! 30+ published and peer-reviewed articles Cancer Area Patients Nr. of studies Strong evidence supporting the use of Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker Gastrointestinal 713 4 of CDK4/6i response Malignant Melanoma 86 2 Collabor
Slide 9: Large market potential in first application!
Large market potential in first application! • Key assumptions: $400 average sales price per test in US, prevalence according to Globocan 2022 • US go to market model: all 50 states served from Biovica CLIA Lab • Other markets: Partner model, where partner introduces DiviTum on the local market • Gr
Slide 11: Key topics: CDK4/6i now approved in early breast cancer
Key topics: 2 CDK4/6i now approved in early breast cancer FDA Project Optimus and optimal dosing Both these areas drives demand for DiviTum® TKa ©2024 Biovica International AB
Slide 12: Biovica Q2 Highlights
Biovica Q2 Highlights US: • Q2 sales are up ~12% vs Q1. • Agreement signed with health-care giant! • CLIA lab now certified for all 50 states in US after New York approval. Pharma Services: • Largest Work Order so far, 50% increase of projects in pipeline • Two new Master Service Agreement, will res
Slide 13: Q2 2024/2025 Significant Events
Q2 2024/2025 Significant Events Significant events during Q2 (August-October) • Biovica signs an agreement with an American biotech company in the clinical phase • Biovica receives significant orders for TKa testing services • Biovica publishes results of series TO3B • Biovica signs a framework agre
Slide 14: Break-through data supports use of DiviTum TKa in early breast cancer!
Break-through data supports use of DiviTum® TKa in early breast cancer! Two trial in early breast cancer with DiviTum TKa Performed by the German Breast Cancer Group and Roswell Park, NY ~1000 patients Conclusion: DiviTum TKa provides value both before and during adjuvant treatment in early breast c
Slide 15: DiviTum TKa in Early and Metastatic Setting
DiviTum TKa in Early and Metastatic Setting • Adjuvant HR+ patients is ~8 times as many as MBC patients • Test frequency will be lower than within MBC • Market potential for DiviTum Tka in BC increases from 600  3 600 MUSD/year • Key driver for demand: the approval of CDK4/6i for adjuvant treatment
Slide 17: YTD Acc Net Sales by Quarter vs PY (KSEK)
YTD Acc Net Sales by Quarter vs PY (KSEK) 8 000 7 000 6 000 5 000 4 316 4 027 4 000 3 000 2 000 1 766 1714 1 000 - Q1 Q2 Q3 Q4 2023/2024 Total 2024/2025 Total ©2024 Biovica International AB
Slide 18: Q2 Sales 24/25 vs Q2 Sales 23/24 (KSEK)
Q2 Sales 24/25 vs Q2 Sales 23/24 (KSEK) 3 000 2 563 2 500 2 312 2 000 1 500 1 000 500 - Q2 24/25 Q2 23/24 IVD Tests (US) IVD Kit (EU) RUO Tests (Research) Divitum Kits (RUO) ©2024 Biovica International AB
Slide 19: Sales development by product Q2 23/24 to Q2 24/25 (KSEK)
Sales development by product Q2 23/24 to Q2 24/25 (KSEK) +54% vs Q1 4 500 4 000 448 3 500 280 631 3 000 2 563 2 500 2 312 -1 610 2 000 1 500 1 000 500 - Q2 23/24 IVD Tests (US) IVD Kit (EU) RUO Tests (Research) Divitum Kits (RUO) Q2 24/25 Increase Decrease Total ©2024 Biovica International AB
Slide 20: YTD US IVD Sales by Quarter (KSEK)
YTD US IVD Sales by Quarter (KSEK) 1 400 1 314 1 200 1 000 788 800 627 600 400 365 200 68 12 - Q1 Q2 Q3 Q4 2023/2024 US IVD 2024/2025 US IVD ©2024 Biovica International AB
Slide 21: Cash flow Q2 23/24 vs Q2 24/25
Cash flow Q2 23/24 vs Q2 24/25 Q2 23/24 Q2 24/25 SEK Millions -5 - 17 - 10 - 24 - 15 -4 - 20 - 25 -4 - 30 Operating Cash flow before change in Working Capital Change in Working Capital* Net Operating Cashflow • Cashflow improved with SEK 7,3M vs same period last year. • However, commercial milestone
Slide 22: Cash Position by quarter (MSEK)
Cash Position by quarter (MSEK) 120,00 100,00 80,00 61,9 60,00 40,00 20,00 - Q1 Q2 Q3 Q4 Cash 2023/2024 Cash 2024/2025 ©2024 Biovica International AB
Slide 23: Q2 FY 2024-25: US Business Update
Q2 FY 2024-25: US Business Update December 2024 ©2024 ©2023 Biovica International AB
Slide 24: Agenda
Agenda Sales Performance Accelerate DiviTum TKa Adoption Focus on IDN’s Regulatory Progress SABCS 2024 ©2024 Biovica International AB
Slide 25: Sales Performance
Sales Performance YTD US IVD Sales by Quarter (KSEK) 1 400 1 314 1 200 Revenue growth in Q2 24/25: 1 000 788 • 10X Q2 23/24 800 627 600 • 12% vs. Q1 24/25 400 365 11% new prescribers ordered DiviTum® 200 TKa 12 68 - Q1 Q2 Q3 Q4 2023/2024 US IVD 2024/2025 US IVD ©2024 Biovica International AB
Slide 26: Accelerate DiviTum TKa Adoption
Accelerate DiviTum TKa Adoption Challenges Opportunities IDN’s ©2024 Biovica International AB
Slide 27: IDNs (Integrated Delivery Networks)
IDNs (Integrated Delivery Networks) Organization that manages end- Some of the top 50 IDNs to-end healthcare facilities of one or more healthcare centers in a defined geographical location. Total US > 500 IDNs Top 10% > 500 BUSD in revenues ©2024 ©2023 Biovica International AB
Slide 28: Benefits of DiviTum TKa for IDN
Benefits of DiviTum TKa for IDN Effective Metastatic Breast B Therapy Cost Cancer Savings i Dose o m Patient’s a Quality of Life Adverse Early Breast r Reaction Cancer k (Adjuvant Therapy) e Early decisions in Prognosis r treatment changes ©2024 Biovica International AB
Slide 29: Regulatory Progress
Regulatory Progress DiviTum is available in 50 states, PR and Washington DC Mar 2023 Oct 2024 Feb 2023 Oct 2023 ©2024 Biovica International AB
Slide 30: 7 posters accepted with DiviTum TKa as biomarker
7 posters accepted with DiviTum TKa as biomarker Evaluation of proliferation biomarker Thymidine kinase activity as a serum thymidine kinase activity and predictive biomarker for benefit to a prediction of early relapse in HR second line CDK4/6 inhibitor: analysis positive HER2 negative high risk ea
Slide 32: The Pharma Services & Collaboration Business
The Pharma Services & Collaboration Business Service Work Order book continues to grow despite a solid execution of Work Orders Sales Continuum TKa Services & Kit Sales - Services under TESA* or MSA** (Multiple projects per MSA): Value:~500k-2.500kSEK per project - Q2: - Signed new Service Work Orde
Slide 33: Q2 Pharma Business Highlights
Q2 Pharma Business Highlights • Signed two new MSA’s with pharma/biotech companies in US and UK • PR’ed 17/9 and 22/10 respectively • Initiated discussions/negotiations on two additional MSA’s • TIER-1* and TIER-2** pharma/biotech companies • Signed record high single Work Order with US based biotec
Slide 35: Summary
Summary Progress and challenges IVD sales (US+EU) H1 1,6 MSEK (68 kSEK) = x 23 PY Commercial milestones delayed, but has now materialized Currently behind plan to become cash-flow positive  refining business plans to address gaps Key Achievements in Q2 to accelerate sales both near and long term Ag
Slide 36: Q&A Session
Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities AG • Luísa Morgado – van Lanschot Kempen 36 ©2024 Biovica International AB

Biovica International — Q2 2025 Earnings Presentation on 6ix

Biovica International Ab Class B — Q2 2025 Earnings Presentation

Slide 1: Biovica International AB

Slide 2: Forward Looking-Statements Disclaimer

Slide 3: Q2 Interim Report

Slide 4: Agenda

Slide 5: Q&A Session

Slide 6: Biovica Introduction

Slide 7: DiviTum TKa

Slide 8: Strong scientific evidence that is still growing!

Slide 9: Large market potential in first application!

Slide 10: Q2 Highlights

Slide 11: Key topics: CDK4/6i now approved in early breast cancer

Slide 12: Biovica Q2 Highlights

Slide 13: Q2 2024/2025 Significant Events

Slide 14: Break-through data supports use of DiviTum TKa in early breast cancer!

Slide 15: DiviTum TKa in Early and Metastatic Setting

Slide 16: Financial Update - Q2 2024/2025

Slide 17: YTD Acc Net Sales by Quarter vs PY (KSEK)

Slide 18: Q2 Sales 24/25 vs Q2 Sales 23/24 (KSEK)

Slide 19: Sales development by product Q2 23/24 to Q2 24/25 (KSEK)

Slide 20: YTD US IVD Sales by Quarter (KSEK)

Slide 21: Cash flow Q2 23/24 vs Q2 24/25

Slide 22: Cash Position by quarter (MSEK)

Slide 23: Q2 FY 2024-25: US Business Update

Slide 24: Agenda

Slide 25: Sales Performance

Slide 26: Accelerate DiviTum TKa Adoption

Slide 27: IDNs (Integrated Delivery Networks)

Slide 28: Benefits of DiviTum TKa for IDN

Slide 29: Regulatory Progress

Slide 30: 7 posters accepted with DiviTum TKa as biomarker

Slide 31: Pharma Services Update

Slide 32: The Pharma Services & Collaboration Business

Slide 33: Q2 Pharma Business Highlights

Slide 34: Summary & QA

Slide 35: Summary

Slide 36: Q&A Session

Slide 37: Biovica International AB